SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending amid community excitement surrounding IRL partnerships, sponsorships of pro athletes like Karolina Arm, and its growing presence in sports culture. The community rallies behind the idea of 'Team SLAP,' emphasizing a lifestyle of excellence and high-performance. Active discussions revolve around the meme's potential for real-world integration and its unique branding.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest Q3 earnings, which revealed a large cash reserve and a shift in equity holdings. Community discussions center around potential buybacks, strategic AI investments in energy, and the implications of Warren Buffett's transition plans. Some analysts are downgrading the stock, while others see opportunity in Berkshire's patient capital approach and potential for future acquisitions.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is trending as the community rallies around recent price movement and anticipates further gains, with some eyeing previous all-time highs. There is ongoing debate about whether it's a legitimate investment or a pump-and-dump scheme, while others express excitement over its potential, comparing it to other popular meme coins. Some community members mention potential listings on major exchanges, and some anticipate significant gains, although opinions on its long-term viability are mixed.

The world's lightest blockchain, powered by participants. Mina is building a privacy-preserving gateway between the real world and crypto — and the infrastructure for the secure, democratic future we all deserve.

Mina Protocol

Mina Protocol is seeing increased discussion as the community debates entry and exit points amidst price fluctuations. Recent news around partnerships and technological upgrades, particularly in zero-knowledge proofs and real-world asset tokenization, are also driving interest. Many traders are closely watching key price levels and speculating on potential breakouts.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors discuss the company's recent Q3 earnings and significant cash reserves, with some suggesting the stock is undervalued. Community members are debating the implications of the large cash position, potential acquisitions, and the impact of Warren Buffett's eventual departure. There is also some discussion on the company's AI investments and comparisons to high-growth tech stocks.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending due to recent price volatility and community speculation about its potential, with some eyeing targets around $5. Discussions include technical analysis with Elliott Wave patterns, potential pullbacks, and whether the recent activity is a pump and dump. The launch of AI agents within the Virtuals ecosystem continues to generate buzz.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is trending amid ongoing discussions about AI's impact on the semiconductor industry and speculation around potential pullbacks. Community members are debating overvaluation concerns, and potential market corrections, while others are optimistic about future growth driven by AI and solid earnings. News about potential tariffs, investments, and company-specific developments are also influencing the conversation.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community eagerly anticipates the upcoming mainnet launch this month, which could bring increased adoption and utility; conversations revolve around potential partnerships and its disruptive potential in the financial sector, fueled by its Google backing and focus on institutional-grade infrastructure. However, not all sentiment is positive, with some users calling the coin trash and questioning its value.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX6900 is trending as community members highlight its potential for significant gains, drawing comparisons to previous meme coin successes. Bullish sentiment is fueled by the coin's strong community and its perceived position as a leading meme coin in the crypto space. Discussions also mention the asset's listing on Coinbase and its potential to "flip the stock market".

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending amid speculation around potential US-China trade resolutions and renewed optimism in Chinese tech, with community members actively discussing long-term growth prospects and AI investments. Some traders are pointing to positive technical indicators and comparing KWEB's valuation to US counterparts, while others remain cautious due to geopolitical uncertainties and past regulatory concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


PESG Report: Silexion Therapeutics Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating...

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

PESG Market Update: Silexion Therapeutics SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new...

Shares of Silexion Therapeutics lost&nbsp;more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late Wednesday.The stock is also on track for its worst day since Dec. 26.The offering includes approximately 3.7 million ordinary shares and accompanying warrants for&nbsp;purchasing up to 3.7 million additional shares.&nbsp;Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.&nbsp;The warrants, which will expire five years from issuance, carry an exercise price of $1.35 and are exercisable immediately. The offering is expected to close on Friday.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLXN_sentiment_and_message_volume_Jan_16_ebe16b64bc.png" alt="SLXN sentiment and message volume Jan 16.png" width="1318" height="324"><figcaption>SLXN sentiment and message volume Jan 16 as of 10 am ET | source: Stocktwits</figcaption></figure>Despite the steep decline in share price, retail sentiment for Silexion was ‘extremely bullish’ on Stocktwits, where message volume surged to a six-month high.&nbsp;Some users voiced plans to buy shares once the offering concludes, while others noted the company’s low float, available cash, and technical levels as reasons for cautious optimism.<stembedurl>https://stocktwits.com/Kevin_Gough/message/600264740</stembedurl><stembedurl>https://stocktwits.com/Patience__/message/600239429</stembedurl><stembedurl>https://stocktwits.com/StockProphercy/message/600293377</stembedurl>Fueling this sentiment further is Wednesday’s release of encouraging preclinical data for Silexion’s experimental pancreatic cancer treatment, SIL-204.&nbsp;According to the company, SIL-204 demonstrated strong synergistic effects when combined with common chemotherapeutic agents, including 5-fluorouracil, irinotecan, and gemcitabine, in human cell lines with KRAS G12D mutations, the most prevalent type of pancreatic cancer.Silexion said it plans to initiate toxicology studies for SIL-204 within the next few months, with phase 2/3 clinical trials scheduled for the first half of 2026.&nbsp;Financially, Silexion ended the third quarter of 2024 with cash and equivalents totaling $2 million and debt near $230,000, according to Koyfin.&nbsp;However, the stock has lost over 98% of its value in the past year, reflecting challenges that may&nbsp;affect its prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment...

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Corp. (NASDAQ: SLXN) (Silexion or the Company), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical...

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer

Silexion Therapeutics Corp. (NASDAQ: SLXN) (Silexion or the Company), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new...

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for...

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Silexion Therapeutics Corp

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$3.40	--	--	N/A
Q2 '25	-$3.15	-$4.32	-37.14%	MISSED
Q1 '25	-$0.22	-$3.90	-1672.73%	MISSED
Q4 '24	-$0.98	--	--	N/A
Q3 '24	-$0.82	--	--	N/A

SLXN
Silexion Therapeutics Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest SLXN News

SLXNSilexion Therapeutics Ltd